Assessment of HPHC Exposure in Smokers Switching to THS/TP18 With Different Device Variants

Recruiting N/A Interventional Study
Smoking
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
21 – 65
Sex
Any
Study type
Interventional
Purpose
Basic Science
Participants needed
108 (estimated)
Sponsor
Philip Morris Products S.A. · Industry
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
This is a randomized, controlled, open-label, 6 parallel arms study to assess reduced exposure of biomarkers of exposure (BoE) of selected HPHC in smokers switching to TP18 (a prototype heated tobacco device) or THS relative to smokers who continue smoking CIG after 5 days of confinement period, followed by 2 days of pharmacokinetic (PK) period of single use of THS/TP18 and CIG, and followed by an…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Participant has signed the ICF and understands the information provided in it. * Participant is male or female and between 21 and 65 years old (inclusive). * Participant has been a smoker for at least 2 years prior to the screening visit and is willing to switch to THS and TP1…
Contacts

Christelle Haziza, PhD

+41 58 242 11 11

christelle.haziza@pmi.com

CONTACT

Sandrine Pouly, PhD

+41 58 242 11 11

CONTACT